These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads. Shahin R, Taha MO. Bioorg Med Chem; 2012 Jan 01; 20(1):377-400. PubMed ID: 22112539 [Abstract] [Full Text] [Related]
4. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors. Suaifan GA, Shehadehh M, Al-Ijel H, Taha MO. J Mol Graph Model; 2012 Jul 27; 37():1-26. PubMed ID: 22609742 [Abstract] [Full Text] [Related]
5. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling. Al-Najjar BO, Wahab HA, Tengku Muhammad TS, Shu-Chien AC, Ahmad Noruddin NA, Taha MO. Eur J Med Chem; 2011 Jun 27; 46(6):2513-29. PubMed ID: 21482446 [Abstract] [Full Text] [Related]
6. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits. Taha MO, Tarairah M, Zalloum H, Abu-Sheikha G. J Mol Graph Model; 2010 Jan 27; 28(5):383-400. PubMed ID: 19850503 [Abstract] [Full Text] [Related]
8. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors. Abuhamdah S, Habash M, Taha MO. J Comput Aided Mol Des; 2013 Dec 27; 27(12):1075-92. PubMed ID: 24338032 [Abstract] [Full Text] [Related]
9. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening. Taha MO, Atallah N, Al-Bakri AG, Paradis-Bleau C, Zalloum H, Younis KS, Levesque RC. Bioorg Med Chem; 2008 Feb 01; 16(3):1218-35. PubMed ID: 17988876 [Abstract] [Full Text] [Related]
10. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads. Al-Nadaf A, Abu Sheikha G, Taha MO. Bioorg Med Chem; 2010 May 01; 18(9):3088-115. PubMed ID: 20378363 [Abstract] [Full Text] [Related]
11. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. Taha MO, Dahabiyeh LA, Bustanji Y, Zalloum H, Saleh S. J Med Chem; 2008 Oct 23; 51(20):6478-94. PubMed ID: 18808096 [Abstract] [Full Text] [Related]
12. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. Abdula AM, Khalaf RA, Mubarak MS, Taha MO. J Comput Chem; 2011 Feb 23; 32(3):463-82. PubMed ID: 20730780 [Abstract] [Full Text] [Related]
13. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Taha MO, Qandil AM, Zaki DD, AlDamen MA. Eur J Med Chem; 2005 Jul 23; 40(7):701-27. PubMed ID: 15935905 [Abstract] [Full Text] [Related]
14. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation. Al-Nadaf AH, Taha MO. J Mol Graph Model; 2011 Apr 23; 29(6):843-64. PubMed ID: 21376648 [Abstract] [Full Text] [Related]
15. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. Abu Hammad AM, Taha MO. J Chem Inf Model; 2009 Apr 23; 49(4):978-96. PubMed ID: 19341295 [Abstract] [Full Text] [Related]
16. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. Taha MO, Al-Sha'er MA, Khanfar MA, Al-Nadaf AH. Eur J Med Chem; 2014 Sep 12; 84():454-65. PubMed ID: 25050878 [Abstract] [Full Text] [Related]
17. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. Al-Masri IM, Mohammad MK, Taha MO. ChemMedChem; 2008 Nov 12; 3(11):1763-79. PubMed ID: 18989859 [Abstract] [Full Text] [Related]
18. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. Al-Sha'er MA, Khanfar MA, Taha MO. J Mol Model; 2014 Jan 12; 20(1):2080. PubMed ID: 24469103 [Abstract] [Full Text] [Related]
19. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets. Shahin R, Swellmeen L, Shaheen O, Aboalhaija N, Habash M. J Comput Aided Mol Des; 2016 Jan 12; 30(1):39-68. PubMed ID: 26685860 [Abstract] [Full Text] [Related]
20. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO. Eur J Med Chem; 2010 Apr 12; 45(4):1598-617. PubMed ID: 20116902 [Abstract] [Full Text] [Related] Page: [Next] [New Search]